Your session is about to expire
← Back to Search
[225Ac]-FPI-2068 for Cancer
Study Summary
This trial tests 3 drugs on people with cancer to measure safety, how drugs spread in body, and how body processes them.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Have the FDA given sanction to Dose Exploration and Dose Escalation?
"As this is an early phase 1 trial, limited evidence supports the safety of Dose Exploration and Dose Escalation which warranted a score of 1."
Are individuals able to join this clinical trial at the present time?
"Reportedly, this clinical trial is now defunct. It was first published on December 30th 2023 but has not been updated since November 27th of the same year; accordingly, it is no longer recruiting patients. Currently though, 4455 other medical studies are actively searching for participants."
What is the ultimate purpose of this clinical experiment?
"According to Fusion Pharmaceuticals Inc., the sponsor of this trial, their primary outcome goal is ascertaining the Maximum tolerated dose of [225Ac]-FPI-2068 and FPI-2053 over a span of 4 years. The secondary objectives include evaluating Tumor uptake of [111In]-FPI-2107 using SPECT/CT or planar imaging as well as measuring changes in Pharmacokinetics parameters such as clearance, AUC, Cmax, and half-life post administration. Additionally, they aim to assess immunogenicity towards each drug through ADA testing."
Share this study with friends
Copy Link
Messenger